Knowledge, attitude and practice toward liraglutide and semaglutide among endocrinology medical staff
Pasquel, F. J., Lansang, M. C., Dhatariya, K. & Umpierrez, G. E. Management of diabetes and hyperglycaemia in the hospital. Lancet Diabetes Endocrinol. 9, 174–188 (2021).
Google Scholar
Association, A. D. 2. Classification and diagnosis of diabetes: standards of medical care in Diabetes-2021. Diabetes Care. 44, S15–s33 (2021).
Google Scholar
Marx, N., Husain, M., Lehrke, M., Verma, S. & Sattar, N. GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes. Circulation 146, 1882–1894 (2022).
Google Scholar
Peimani, M. et al. Patient-physician interpersonal processes of care at the time of diabetes treatment intensification and their links to patient outcomes. Patient Educ. Couns. 104, 1659–1667 (2021).
Google Scholar
Rubino, D. M. et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA 327, 138–150 (2022).
Google Scholar
Nauck, M. A., Quast, D. R., Wefers, J. & Meier, J. J. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol. Metab. 46, 101102 (2021).
Google Scholar
Lin, D. S., Lee, J. K., Hung, C. S. & Chen, W. J. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials. Diabetologia 64, 2676–2686 (2021).
Google Scholar
Sodhi, M., Rezaeianzadeh, R., Kezouh, A. & Etminan, M. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. Jama 330, 1795–1797 (2023).
Google Scholar
Xie, Z., Yang, S., Deng, W., Li, J. & Chen, J. Efficacy and safety of liraglutide and semaglutide on weight loss in people with obesity or overweight: A systematic review. Clin. Epidemiol. 14, 1463–1476 (2022).
Google Scholar
Garvey, W. T. et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat. Med. 28, 2083–2091 (2022).
Google Scholar
Long, B., Pelletier, J., Koyfman, A. & Bridwell, R. E. GLP-1 agonists: A review for emergency clinicians. Am. J. Emerg. Med. 78, 89–94 (2024).
Google Scholar
Healy, A. M. et al. Endocrinologists’ opinions of diabetology as a primary care subspecialty. Clin. Diabetes. 36, 168–173 (2018).
Google Scholar
AshaRani, P. V. et al. Study protocol for a nationwide knowledge, attitudes and practices (KAP) survey on diabetes in Singapore’s general population. BMJ Open. 10, e037125 (2020).
Google Scholar
Qi, J. Y. et al. Assessment of knowledge, attitude, and practice regarding diabetic retinopathy in an urban population in Northeast China. Front. Public. Health. 10, 808988 (2022).
Google Scholar
Poudel, P. et al. Oral health knowledge, attitudes and care practices of people with diabetes: a systematic review. BMC Public. Health. 18, 577 (2018).
Google Scholar
Wang, H. et al. Knowledge, attitudes, and practice of endocrinology healthcare workers regarding screening for pre-ulcerative diabetic foot lesions. J. Tissue Viability. 32, 472–479 (2023).
Google Scholar
Edwards, K., Li, X. & Lingvay, I. Clinical and safety outcomes with GLP-1 receptor agonists and SGLT2 inhibitors in type 1 diabetes: a real-world study. J. Clin. Endocrinol. Metabolism. 108, 920–930 (2023).
Google Scholar
Wan, J., Ferrari, C. & Tadros, M. GLP-1RA essentials in gastroenterology: side effect management, precautions for endoscopy and applications for Gastrointestinal disease treatment. Gastroenterol. Insights. 15, 191–212 (2024).
Johansen, P. et al. Evaluating the long-term cost-effectiveness of once-weekly semaglutide versus once-daily liraglutide for the treatment of type 2 diabetes in the UK. Adv. Therapy. 37, 2427–2441 (2020).
Google Scholar
Fernando, K., Bain, S. C., Holmes, P., Jones, P. N. & Patel, D. C. Glucagon-Like peptide 1 receptor agonist usage in type 2 diabetes in primary care for the UK and beyond: A narrative review. Diabetes Ther. 12, 2267–2288 (2021).
Google Scholar
Aldhobaib, A. Y., Rabbani, S. I. & Mobark, M. A. Knowledge Attitude and practice about a newer class of antidiabetic drug (Glucagon-like peptide-1 receptor agonist) among the health care professionals of Qassim university. J. Pharm. Res. 20, 58–66 (2021).
Li, C. et al. Real-world National trends and socio-economic factors preference of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in China. Front. Endocrinol. (Lausanne). 13, 987081 (2022).
Google Scholar
Li, Y. et al. Mastery of type 2 diabetes prevention and treatment knowledge by general practitioners in Shanghai: a cross-sectional study. BMC Fam Pract. 22, 189 (2021).
Google Scholar
Karas, M., Sheen, N. J. L., North, R. V., Ryan, B. & Bullock, A. Continuing professional development requirements for UK health professionals: a scoping review. BMJ Open. 10, e032781 (2020).
Google Scholar
Li, Y., Gong, W., Kong, X., Mueller, O. & Lu, G. Factors associated with outpatient satisfaction in tertiary hospitals in China: a systematic review. Int. J. Environ. Res. Public Health. 17, 7070 (2020).
Google Scholar
Islam, M. S. et al. Knowledge, attitudes and perceptions towards COVID-19 vaccinations: a cross-sectional community survey in Bangladesh. BMC Public. Health. 21, 1–11 (2021).
Google Scholar
Papagiannis, D. et al. Assessment of knowledge, attitudes, and practices towards new coronavirus (SARS-CoV-2) of health care professionals in Greece before the outbreak period. Int. J. Environ. Res. Public Health. 17, 4925 (2020).
Google Scholar
Igarashi, A. et al. Preference for oral and injectable GLP-1 RA therapy profiles in Japanese patients with type 2 diabetes: A discrete choice experiment. Adv. Ther. 38, 721–738 (2021).
Google Scholar
Knop, F. K. et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 402, 705–719 (2023).
Google Scholar
Jape, D., Zhou, J. & Bullock, S. A spaced-repetition approach to enhance medical student learning and engagement in medical Pharmacology. BMC Med. Educ. 22, 337 (2022).
Google Scholar
Uzoigwe, C., Liang, Y., Whitmire, S. & Paprocki, Y. Semaglutide once-weekly persistence and adherence versus other GLP-1 RAs in patients with type 2 diabetes in a US real-world setting. Diabetes Ther. 12, 1475–1489 (2021).
Google Scholar
Müller, T. D., Blüher, M., Tschöp, M. H. & DiMarchi, R. D. Anti-obesity drug discovery: advances and challenges. Nat. Rev. Drug Discov. 21, 201–223 (2022).
Google Scholar
Evans, M., Berry, S., Malkin, S. J. P., Hunt, B. & Sharma, A. Evaluating the long-term cost-effectiveness of once-weekly semaglutide 1 mg versus liraglutide 1.8 mg: A health economic analysis in the UK. Diabetes Ther. 14, 1005–1021 (2023).
Google Scholar
Bernardi, R. A. & Nash, J. The importance and efficacy of controlling for social desirability response bias. Ethics Behav. 33, 413–429 (2023).
Google Scholar
link
